Results 231 to 240 of about 440,184 (328)

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical Cancer Research, 2015
Hyon-Zu Lee, V. Kwitkowski, P. D. Del Valle, M. S. Ricci, H. Saber, B. Habtemariam, J. Bullock, E. Bloomquist, Yuan Li Shen, Xiao-Hong Chen, Janice Brown, Nitin Mehrotra, Sarah E Dorff, R. Charlab, Robert C. Kane, E. Kaminskas, R. Justice, A. Farrell, R. Pazdur   +18 more
semanticscholar   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure‐response (E‐R) relationships of selected efficacy and ...
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
wiley   +1 more source

Primary bone ALK-positive anaplastic large cell lymphoma presented as a giant extraskeletal mass with coagulation necrosis. [PDF]

Radiol Case Rep
Nagata S, Sawano M, Shouji Y, Oka M, Kurata S, Hiraoka K, Akiba J, Tanoue S.   +7 more
europepmc   +1 more source

An Up‐to‐Date Review of Traditional Chinese Medicine in the Treatment of Atherosclerosis: Components, Mechanisms, and Therapeutic Potentials

Phytotherapy Research, EarlyView.
Traditional Chinese medicine in atherosclerosis: multi‐target modulation of pathogenesis. ABSTRACT Atherosclerosis is a chronic inflammatory disease and a major global health concern. In recent years, traditional Chinese medicines (TCMs) have demonstrated multi‐target therapeutic potential against atherosclerosis by modulating inflammatory responses ...
Dilaram Nijat, Qingzhe Zhao, Gulhasal Abdurixit, Jianhua He, Haipeng Liu, Jinyao Li   +5 more
wiley   +1 more source

Bystander CAR^-CD8⁺ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody. [PDF]

J Immunother Cancer
Kato J, Konishi T, Honda T, Maruta M, Nabe S, Masuda Y, Matsumoto M, Kawasaki N, Miyazaki Y, Doi Y, Takasuka Y, Yamanouchi J, Ochi T, Takenaka K.   +13 more
europepmc   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, Volume 21, Issue 29, July 24, 2025.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances. [PDF]

Clin Exp Med
Feng Y, Ma Y, Li T, Liu M, Hong Z, Yin Q, Zheng M.   +6 more
europepmc   +1 more source

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma [PDF]

, 2019
Bantilan, Kurt, Horwitz, Steven M., Ito, Kimiteru, Mehta-Shah, Neha, Moskowitz, Alison J., Sauter, Craig, Schoder, Heiko   +6 more
core   +1 more source

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Therapeutic Advances in Hematology, 2015
A. Sawas, D. Radeski, O. O’Connor
semanticscholar   +1 more source

Cystoid Macular Edema Secondary to Hyperviscosity Syndrome in Waldenström Macroglobulinemia: A Case Report of Multimodal Treatment Response and the Adjunctive Role of Acetazolamide

The Kaohsiung Journal of Medical Sciences, EarlyView.
Yu‐Mei Yang, Chuan‐Cheng Wang, San‐Ni Chen, Jian‐Sheng Wu   +3 more
wiley   +1 more source